$BVS Cashflow Statement | Understand Stock

$BVS

$14.42 -$0.30 (2.04%) Close

$BVS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities:
Net income (loss)
Less: Loss from discontinued operations, net of tax
Income (loss) from continuing operations
Adjustments to reconcile net income (loss) to net cash from operating activities:
Depreciation and amortization
Payment of contingent consideration in excess of amount established in purchase accounting
Provision (benefit) for expected credit losses
Equity-based compensation
Profits interest plan, liability-classified and other equity awards compensation
Change in fair value of contingent consideration
Change in fair value of interest rate swap
Change in fair value of Equity Participation Rights unit
Impairments of assets
Impairments related to variable interest entity
Loss on extinguishment
Revaluation gain on previously held equity interest in CartiHeal
Loss on disposals
Deferred income taxes
Change in fair value of Equity Participation Rights
Unrealized (gain) loss on foreign currency fluctuations
Other, net
Changes in operating assets and liabilities:
Accounts receivable
Inventory
Accounts payable and accrued expenses
Other current and noncurrent assets and liabilities

Net cash from operating activities - continuing operations
Net cash from operating activities - discontinued operations
Net cash from operating activities
Investing activities:
Acquisitions, net of cash acquired
(Settlement) proceeds from the sale of a business
Purchase of property and equipment
Investments and acquisition of distribution rights
Other
Net cash from investing activities - continuing operations
Net cash from investing activities - discontinued operations
Net cash from investing activities
Financing activities:
Proceeds from issuance of Class A common stock sold in initial public offering, net of underwriting discounts and offering costs
Proceeds from issuance of Class A and B common stock
Registration fees for Class A common stock to purchase Misonix
Tax withholdings on equity-based compensation
Receipt of deferred consideration
Payment of contingent consideration
Borrowing on revolver
Payment on revolver
Proceeds from the issuance of long-term debt, net of discount
Payments on the extinguishment of long-term debt
Debt financing costs
Payments on long-term debt
Distributions to members
Other, net
Net cash from financing activities

Effect of exchange rate changes on cash
Net change in cash and cash equivalents
Cash and cash equivalents at the beginning of the period
Cash and cash equivalents at the end of the period
Supplemental disclosure of noncash investing and financing activities
Accrued liabilities for distribution rights
Debt conversion
Accrued liabilities for distribution rights and member distributions
Accounts payable for purchase of property, plant and equipment

Comments